Join →

Sonoma Biotherapeutics

By expanding and enhancing a patient’s own TReg cells, Sonoma is developing therapies that don’t just suppress symptoms but instead reset immune equilibrium.

Three researchers in lab coats reviewing results on a tablet
Photo: National Cancer Institute on Unsplash
There is no doubt that cell and gene therapy is the future for medicine and the way we develop drugs. It’s hard, it’s risky and it’s going to take us a while, but it will be a new pillar of medicine.
Jeffrey BluestonePresident and CEO, Co-Founder, Sonoma Biotherapeutics
Concept redesign · not the official Biocom site